This biomarker combination (TIMP-2 × IGFBP-7) is the only Food and Drug Administration-approved product for use in risk assessment for AKI in critically ill patients in the United States (NephroCheck) [29]. This evidence concerns the gene IGFBP7 and acute kidney injury.